Overview

Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma

Status:
Recruiting
Trial end date:
2022-12-03
Target enrollment:
Participant gender:
Summary
Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University Hospital Hradec Kralove
Collaborators:
Bristol-Myers Squibb
GCP-Service International s.r.o.
Treatments:
Nivolumab